Lipid Nanoparticle RNA Expression Compositions for Flexible Storage

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Alphavirus-based RNA expression systems suffer from instability during storage and require impractical low temperature conditions, hindering their ease of use and storage.

Innovation Solution

Formulations of RNA-based expression systems encapsulated in lipid nanoparticles, combined with a buffer and stabilizing excipients, enhance stability at various temperatures.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Stability of the object's composition

If RNA-based expression systems are stored at low temperatures, then stability is improved, but ease of storage and handling deteriorates due to impractical storage conditions

Engineering Contradiction:

ImprovestabilityVSAvoidease of storage

Core Design Contradiction:

Stability of the object's compositionVSEase of operation

Solution Approach 1:

The patent changes the storage temperature parameter from impractical low temperatures to a broader range including -78°C to 35°C, making storage more practical while maintaining stability through formulation improvements

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces stabilizing excipients and buffer systems as intermediary substances that mediate between the RNA-based expression system and the storage environment, enabling stability across a wider temperature range without requiring impractical storage conditions

Inventive Principle:

Principle #24Intermediary (Mediator)

2Stability of the object's composition

If RNA-based expression systems are stored at impractical low temperatures, then stability is maintained, but device complexity increases

Engineering Contradiction:

ImprovestabilityVSAvoidstorage complexity

Core Design Contradiction:

Stability of the object's compositionVSDevice complexity

Solution Approach 1:

The patent modifies the storage temperature parameter to allow storage at -78°C to 35°C, eliminating the need for complex cryogenic storage systems while maintaining stability through optimized formulation

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs stabilizing excipients and buffer systems as intermediaries that protect the RNA-based expression system from degradation, enabling simplified storage conditions without compromising stability

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250302946A1Compositions and methods of use thereof

Publication Date: 2025.10.02 SEATTLE PROJECT CORP

AI summary

Disclosed herein are a pharmaceutical composition comprising an RNA-based expression system suitable for storage and methods of making and using the same.